A John Iafrate

Plain English
Researchers tested a drug called crizotinib on cancer patients whose tumors had specific genetic mutations in a gene called MET. They found the drug worked in about 14% of patients in both groups, shrinking tumors or stopping growth temporarily, though most patients' cancers eventually progressed. The key finding was that patients with one type of mutation (METex14) responded better when they had higher levels of the genetic change—these patients stayed disease-free for about 8.8 months compared to 1.7 months for those with lower levels. This suggests doctors may need to measure how much of the mutation is present to predict whether the drug will actually work.

Plain English
Researchers tested a drug called abemaciclib on patients with aggressive brain tumors (meningiomas) that had come back after surgery or radiation treatment. These tumors had specific genetic mutations that make them grow faster, and currently there are few effective drug options for this group of patients. The drug worked: 58% of patients saw their tumors stop growing or shrink for at least 6 months, which met the study's success threshold. Most side effects were manageable, though a few patients experienced serious liver problems or severe vomiting. This matters because meningioma patients with these genetic mutations have very limited treatment options—this drug offers a new possibility that slows tumor growth and is tolerable enough for patients to continue taking it.

Plain English
Researchers developed a blood test that detects HPV cancer DNA years before oropharyngeal cancer (a common throat cancer) develops, finding the virus DNA in 79% of patient blood samples taken up to 7.8 years before diagnosis, while showing no false positives in healthy people. Using advanced computer analysis, they improved the test to detect the cancer signal in 96% of cases up to 10 years before symptoms appear. This discovery could enable doctors to catch this aggressive cancer much earlier, when treatment is more likely to succeed and causes less harm.

Plain English
Researchers tested a new two-drug combination (olaparib and temozolomide) against rhabdomyosarcoma, a childhood muscle cancer, and found it worked well initially—but more than half the tumors eventually became resistant to the treatment. They discovered that resistant tumors activate a specific cellular pathway (PIK3CA/AKT) that pumps the drugs out of cancer cells, allowing them to survive. Adding a third drug (alpelisib) that blocks this pathway restored the treatment's effectiveness by stopping the cancer cells from ejecting the drugs. In mouse experiments, this three-drug combination killed even the toughest, drug-resistant tumors and stopped their growth. This finding could lead to a better treatment strategy for children whose rhabdomyosarcoma stops responding to standard chemotherapy.

Plain English
Researchers developed a highly sensitive blood test that detects tiny amounts of HPV cancer DNA left in patients after surgery for HPV-related head and neck cancer. They found that patients whose blood still contained this cancer DNA had much worse outcomes—only 60% stayed cancer-free for 2 years compared to 100% of patients with no detectable DNA—and this blood test was better at predicting who would relapse than current methods doctors use. The test could also spot cancer coming back up to 17 months before it shows up on scans or causes symptoms, giving doctors an early warning system to decide whether patients need additional treatment like chemotherapy or radiation.

Plain English
Researchers analyzed tumors from mesothelioma patients to understand how genetic mutations affect the immune cells present in the tumor and how well patients respond to immunotherapy drugs. They found that tumors with mutations in MTAP or CDKN2A genes had very few immune cells, while tumors with NF2 mutations had more immune cells—but surprisingly, having more immune cells didn't automatically mean the drug worked better. The study matters because doctors currently treat mesothelioma based only on tumor appearance under a microscope, ignoring these genetic mutations that significantly change how well immunotherapy works. Using genetic testing to identify which patients have BAP1 mutations (who respond well) versus CDKN2A or NF2 mutations (who don't) could help doctors choose better treatments and predict which patients will benefit from this expensive drug combination.

Plain English
Researchers tested 26 different laboratories across the United States to see if their DNA sequencing machines and analysis methods produced the same results when analyzing cancer tumors for the NCI-MATCH clinical trial. They found that all the machines detected genetic changes with very high accuracy (over 95%), but the final reports doctors received varied significantly depending on which laboratory analyzed the sample—mainly because different labs used different computer software to filter and interpret the raw data. This matters because patients with cancer need accurate genetic test results to get the right targeted drugs, and these findings show that a patient could receive different treatment recommendations depending solely on which laboratory ran their test, not because the machines are faulty but because labs handle the data differently after detection.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
Researchers tested whether a simple blood test could detect the same cancer-causing genetic mutations that doctors found in tumor tissue samples from cancer patients. They found that the blood test successfully identified the mutation in 81% of patients when the blood and tissue samples were collected around the same time, but only 56% of the time when the samples were collected far apart. This matters because blood tests are much easier and less invasive than biopsies, so if they work reliably, doctors could use them instead of surgery to identify which patients qualify for specific cancer treatments.

Plain English
Adenoid cystic carcinoma (ACC) is a deadly cancer that doesn't respond well to current treatments because tumors hide from the immune system—they have very low levels of a protein called HLA class I that the immune system needs to recognize and attack cancer cells. Researchers discovered that treating ACC tumors with immune-activating drugs called STING agonists can turn this protein back on, and when they tested this approach in one patient combined with an existing immunotherapy drug, the tumor shrank by 70%. This finding suggests that turning HLA class I back on with STING agonists could finally make immunotherapy work for ACC patients.

Plain English
Researchers studied eight rare cancers that formed in the urethra (the tube that carries urine) and found that all of them had mutations in two genes called KRAS and EGFR, whether or not the patients had previously received radiation therapy for prostate cancer. The cancers were typically large (about 3.4 centimeters), required surgical removal of the urethra and nearby organs, and two patients died from the disease while others survived with follow-up care. This discovery matters because identifying these specific genetic mutations could lead to new targeted treatments for this extremely rare cancer, and it shows that radiation exposure isn't the only way these tumors develop.

Plain English
Researchers tested 380 blood cancer samples using two different methods to find genetic changes that affect treatment—one traditional method that looks at whole chromosomes and a newer method that examines specific genes. The newer genetic test caught important abnormalities that the older method missed in about 10% of cases, but surprisingly, in rare cases (3 patients), the older method falsely appeared to find a known dangerous genetic change that wasn't actually there. This matters because doctors rely on these genetic findings to choose the right treatment, so a false positive can lead to unnecessary or wrong treatment decisions. The study shows that blood cancer diagnosis should use gene-level tests, not just chromosome-level tests, to avoid these dangerous mistakes.

Plain English
Researchers found that some aggressive breast cancers have a specific genetic pattern: extra copies of two genes called ERBB2 and HOXB13 appearing together, along with a lost tumor-fighting gene called BRCA1. This combination appears mostly in breast cancers and rarely in other cancer types. Patients with this genetic pattern got worse much faster than patients whose cancers only had extra ERBB2 copies, particularly in breast cancers that don't respond to hormone therapy. This matters because doctors can now identify a subgroup of breast cancer patients who need more aggressive treatment, and this genetic signature could help guide which therapies will work best.

Plain English
Researchers created lab versions of over 130 different COVID mutations that have emerged over the past four years to test how well vaccine-produced antibodies could neutralize them. They found that the virus is continuously mutating in ways that help it escape antibodies from mRNA vaccines, and newer variants like JN.1, KP.2, and KP.3 are particularly good at getting around even the latest boosters. This matters because it shows that our current vaccine strategy alone won't stop COVID from spreading indefinitely—the virus is outpacing our vaccine updates, so scientists need to develop new approaches to keep people protected.

Plain English
Researchers screened 5,540 cancer patients for genetic mutations that could guide treatment, but their testing method missed many gene fusions—a type of genetic abnormality where two genes get stuck together. When they re-tested 663 of the patients with a more advanced detection method, they found gene fusions in 21% of them, including 32 cases with fusions that could be treated with existing drugs that the original screening had missed. This matters because many cancer patients aren't getting treatment options they should have access to, simply because the standard genetic testing used in clinics isn't good enough at finding gene fusions, especially new ones doctors haven't seen before.

Plain English
Researchers tested 35 tumors called adenoid cystic carcinomas to see which method best detects a cancer-driving gene called MYB. They compared four different antibody tests (which look for the MYB protein under a microscope) against a genetic sequencing test (which detects MYB gene fusions directly). They found that the antibody tests gave wildly different results depending on which one was used—ranging from catching 26% to 97% of cases—while genetic sequencing found the MYB problem in 54% of cases. This matters because doctors need reliable tests to diagnose this cancer type and guide treatment, but the results showed that the antibody tests are inconsistent and don't always match what the genetic test finds, meaning doctors need to be careful about which test they choose and may need to combine multiple tests to get accurate results.

Plain English
Researchers looked at 5,030 thyroid cancer samples and found 17 tumors with mutations in a specific gene family—11 where this mutation was the main cancer driver and 6 where it was a secondary mutation that might help cancer resist treatment. They discovered that some of these mutations could be targeted with existing drugs, but doctors aren't currently looking for them because they're not well-known. This matters because identifying these mutations in thyroid cancer patients could open up new treatment options that don't work for other types of thyroid cancer, potentially improving outcomes for people who have these specific mutations.

Plain English
Researchers gave COVID-19 vaccines to 117 adults with a rare immune disease that prevents them from making enough antibodies, then tracked how well their bodies responded compared to 192 healthy people. People with the immune disease produced much lower levels of protective antibodies after the first few shots, but their antibody levels kept climbing with each additional dose, eventually reaching levels that could neutralize both the original COVID strain and newer variants like Omicron. The study shows that people with this immune disease benefit from getting more vaccine doses—especially those with the most severe form of the condition—because each shot progressively strengthens their immune response, even if they never catch up to healthy people's antibody levels.

Plain English
Researchers tested blood samples from vaccinated people against 48 different COVID variants to see if their immunity could keep up with the virus's changes. They found that while booster shots helped fight most older variants, newer variants like JN.1 still managed to escape the vaccine's protection, and each new variant was progressively harder for the immune system to neutralize. This matters because it shows that updated boosters can help temporarily, but the virus keeps evolving faster than we can update vaccines, meaning we need completely new strategies beyond just tweaking the existing vaccine to control COVID transmission.

Plain English
Researchers developed a blood test that can detect a common cancer caused by HPV (the virus linked to cervical cancer) years before symptoms appear—up to 10 years early in some cases. The test works by finding tiny pieces of HPV DNA floating in the bloodstream, which the cancer releases long before the disease becomes noticeable. When they tested blood samples taken years before patients were actually diagnosed with cancer, the test caught 79% of future cancer cases while giving zero false alarms in healthy people. Using artificial intelligence to analyze the blood samples improved detection even further, catching 96% of cases. This matters because unlike cervical cancer, there's currently no screening test for this type of HPV-related throat cancer—the most common HPV cancer in America. A blood test that finds it a decade early could save lives by catching cancer when it's easiest to treat.

Plain English
Researchers created a virtual clinic where community and hospital cancer doctors could quickly consult with genomic experts about patients with advanced breast cancer to find appropriate clinical trials and genetic tests. Over two years, the clinic reviewed 81 patients from 22 different doctors, gave recommendations within two days on average, and successfully got one-third of those patients enrolled in clinical trials—with 92% of referring doctors saying they'd use the service again. This matters because patients with advanced breast cancer often can't access genetic testing or clinical trials that might help them, especially those treated at smaller community hospitals far from major medical centers; this virtual clinic model bridges that gap and gets more patients into potentially life-saving treatments faster.

Plain English
Researchers studied people who lack B cells (immune cells that normally make antibodies) due to either a genetic condition or cancer treatment, and compared their immune response to COVID-19 infection and vaccines against healthy people. They found that people without B cells actually developed stronger T cell responses (a different type of immune cell) to the virus, and vaccinated patients without B cells had about 5 times lower odds of getting severely ill with COVID-19, even though they couldn't make antibodies. This matters because it shows that T cells alone can protect against severe COVID-19 without antibodies, which could change how we think about immunity to the virus and might help doctors better protect people who can't make antibodies due to disease or treatment.

Plain English
Researchers studied seven rare breast lesions (four pre-cancerous and three early-stage cancerous growths) found between 2010 and 2022 to identify genetic mutations associated with them. They discovered that most of these lesions contained mutations in a gene called TP53, which normally prevents cancer from developing. This finding matters because these rare breast lesions are poorly understood, and identifying TP53 mutations could help doctors better predict which patients are at higher risk for developing invasive breast cancer and potentially guide treatment decisions.

Plain English
Researchers studied 847 patients with cholangiocarcinoma (bile duct cancer) to compare outcomes between people under 50 and those over 50, finding that younger patients had more aggressive tumors at the time of surgery but were more likely to receive multiple types of treatment, including newer targeted therapies and experimental clinical trials. Despite having more advanced disease, younger patients actually survived longer than older patients—about 17.7 months versus 13.5 months for those with advanced cancer. These findings are encouraging because they show that younger people with this rare cancer respond better to treatment and are getting access to newer therapeutic options, which could help improve outcomes for this age group.

Plain English
Researchers created a fast-track program to quickly identify a specific genetic mutation in lung cancer patients and get them the right drug (osimertinib) as fast as possible by having radiologists, pathologists, and pharmacists work in parallel instead of sequentially. The program cut the time from taking a tissue sample to getting test results down to just 1 day (versus 17 days in normal workflows) and reduced the time from diagnosis to starting treatment from over a year to just 5 days, with some patients receiving the drug within 24 hours of confirmation. This matters because patients with this specific mutation respond much better to osimertinib than standard chemotherapy, so reducing delays by months or even weeks can significantly improve their chances of survival.

Plain English
Researchers tested a drug combination (vemurafenib-cobimetinib) on 16 patients with a specific type of brain tumor called papillary craniopharyngioma, which usually requires surgery or radiation that can cause serious side effects like vision loss and memory problems. The drug combination shrank tumors in 15 of the 16 patients by an average of 91%, and most patients remained tumor-free for at least a year without needing surgery or radiation. The main drawback was that the drugs caused significant side effects in most patients, including severe rashes and other problems that led three patients to stop treatment.

Plain English
Researchers studied 39 patients with mucosal melanoma (a rare and deadly cancer that grows in the mouth, nose, or other internal surfaces) to identify which patients would survive longer or shorter after diagnosis. They found that patients whose tumors lacked pigmentation (color) and those carrying specific genetic mutations (NRAS or KRAS) died significantly sooner than other patients. This matters because doctors now have two concrete warning signs that tell them which mucosal melanoma patients need more aggressive treatment and closer monitoring—information that was previously unknown for this type of cancer.

Plain English
Researchers tested whether matching cancer drugs to genetic mutations in individual tumors would work better than traditional treatment approaches. They screened nearly 6,000 cancer patients, identified genetic mutations in their tumors, and assigned 1,593 patients to 27 different treatment groups based on their specific mutations—each group tested a different drug-mutation pairing. The trial found that about one-quarter of these drug-mutation combinations actually shrank tumors, which confirmed that this strategy can work for some patients. The trial revealed both successes and failures that will help doctors design better precision medicine trials in the future, where treatment is tailored to each patient's cancer genetics rather than giving everyone the same drug.

Plain English
Researchers tested a new breast cancer drug called elacestrant on cancer cells from patients whose tumors had stopped responding to previous hormone-blocking treatments, including a drug called fulvestrant. They found that elacestrant worked better than standard treatments in these resistant cases, regardless of specific genetic mutations in the cancer cells. This matters because many women with advanced hormone-positive breast cancer eventually develop resistance to available drugs, leaving them with limited options—elacestrant appears to be an effective next step for patients whose cancer has already failed other hormone therapies.

Plain English
Researchers identified a set of genes that predict whether patients with a specific type of breast cancer will respond well to the drug abemaciclib after their cancer has stopped responding to an earlier drug called palbociclib. Patients without these resistance genes lived twice as long before their cancer progressed again (7 months versus 3.5 months) compared to those with the genes, meaning the gene panel can help doctors choose the right patients for this drug. This matters because it gives doctors a way to predict which patients will benefit from abemaciclib versus those who should try a different treatment, potentially helping them avoid wasting time on ineffective drugs and get to better options faster.

Plain English
Researchers tracked blood tests that measure HPV DNA in two throat cancer patients to monitor their disease during and after treatment. Both patients unexpectedly developed a second separate HPV-related cancer while being treated for their first one, which made the blood test results confusing because the test couldn't tell which cancer the detected DNA was coming from. This matters because as doctors increasingly use this blood test to catch cancer recurrence early, they need to know that rising levels don't always mean the original cancer is coming back—a patient might have developed a completely new cancer instead, which requires different treatment decisions.

Plain English
Researchers compared how doctors treat two types of bile duct cancer—one that starts inside the liver and one that starts outside it—and found that patients with the outside type are more likely to have surgery and receive chemotherapy after surgery, but less likely to have their tumors genetically tested or receive newer targeted drugs. Patients with the inside type of bile duct cancer received genetic testing and advanced treatments more often, lived slightly longer on average, and had better access to experimental therapies, though both types of cancer remain difficult to treat and have poor survival rates. The study shows that patients with outside bile duct cancer are missing out on potentially helpful genetic testing and newer drugs, largely because there isn't enough tumor tissue to test, and doctors need to find better ways to identify which patients could benefit from these advanced treatments.

Plain English
Researchers tested how location bias affects COVID-19 antibody surveys that recruit people from specific neighborhoods rather than randomly across entire cities. They found that when surveys recruit heavily from one area, they get inaccurate results if that area had either more or fewer COVID cases than surrounding neighborhoods—and the problem gets worse when overlooked neighborhoods have larger populations. The researchers developed a solution: they used smartphone location data to identify which recruitment locations would capture people from across the entire city more fairly, which made their COVID antibody estimates more accurate and reliable. This matters because many public health decisions rely on these antibody surveys to understand how many people have been infected with COVID, so getting better, more geographically representative data helps cities and health agencies plan response strategies more effectively.

Plain English
Researchers tracked 242 lung cancer patients to see how many got COVID-19 vaccines and boosters, finding that while 75% got a third dose, only 39% got a fourth dose, and just 5% got a fifth dose. The study confirmed that extra vaccine doses did boost immune protection in the patients who received them. Because lung cancer patients face serious risks from COVID-19, doctors need to better understand why these patients aren't getting boosters and should spend more time discussing vaccine recommendations with them.

Plain English
Researchers tested a new drug called GSK2256098 on 36 patients with brain tumors called meningiomas that had come back or were getting worse—specifically those with a genetic mutation called NF2. The drug worked better for less aggressive tumors: 83% of grade 1 patients stayed tumor-free for at least 6 months, compared to only 33% of more aggressive grade 2/3 patients, and the drug caused only minor side effects. This matters because meningioma patients with this genetic mutation currently have very few treatment options, and this drug showed enough promise that doctors should continue testing it, particularly for the less aggressive tumors where it performed well.

Plain English
Researchers tested how well COVID-19 vaccines worked in breast cancer patients by measuring antibody levels after vaccination, and found that the Moderna vaccine produced stronger immune responses than Pfizer or Johnson & Johnson vaccines, while chemotherapy drugs weakened the body's ability to build antibodies compared to patients on hormone therapy or no treatment. Most breast cancer patients still developed some antibodies to COVID-19, but those undergoing active chemotherapy had noticeably weaker immune responses. This matters because it shows that breast cancer patients may need different vaccination strategies depending on their treatment type, and doctors might need to consider giving extra vaccine doses to those on chemotherapy to ensure adequate protection.

Plain English
Researchers studied rhabdomyosarcoma, a common childhood muscle cancer, and discovered it grows from muscle cells that are stuck at specific early developmental stages—as if the cancer cells never finished maturing into adult muscle. They found two main types of these cancers: one resembles muscle cells from early fetal development, while the other resembles muscle cells from a specific 7-week point in fetal development and oddly also activates nerve-related genes. The most important finding is that they identified the exact cancer cells responsible for spreading the disease, and these cells behave like early-stage progenitor cells that normally have the potential to become either muscle or bone cells.

Plain English
Researchers compared the types of antibodies that people developed after COVID-19 infection, looking at whether different antibodies appeared depending on how sick people got—from no symptoms to severe hospitalization. They found that people who had worse COVID-19 developed a broader range of antibodies, and they identified specific antibody targets that appeared only in certain severity groups, including some antibodies that might protect against severe illness. This matters because understanding which antibodies correlate with mild versus severe disease could help doctors create better vaccines, design more effective treatments, and develop diagnostic tests that predict how seriously someone will be infected.

Plain English
Researchers tested 8,106 tumors to see if a genetic change called MAML2 could help doctors diagnose mucoepidermoid carcinoma, a type of salivary gland cancer that's often confused with a more dangerous cancer called adenosquamous carcinoma. They found that MAML2 testing was present in most head and neck cancers (about 6% of them) and correctly identified mucoepidermoid carcinoma 60% of the time, but more importantly, it was excellent at ruling out the aggressive adenosquamous carcinoma—meaning it changed the diagnosis in nearly a quarter of cases. This test is most useful for confirming a suspected diagnosis or ruling out the more dangerous cancer type, which helps doctors make sure patients get the right treatment.

Plain English
Researchers tested how well COVID-19 vaccines worked in 62 patients with antibody deficiency disorders—conditions that cripple the immune system's ability to fight infections—and compared them to healthy people. Patients with antibody deficiency produced far fewer protective antibodies from COVID-19 vaccines than healthy people did, and those with the most severe immune problems barely responded at all, especially if they'd recently had treatments that destroy B cells (immune cells that make antibodies). A booster shot with an mRNA vaccine (Pfizer or Moderna) dramatically improved antibody levels in most of these patients, suggesting that extra doses could protect this vulnerable population from severe COVID-19.

Plain English
Researchers tested whether people's immune cells (called T cells) could still recognize the Omicron variant of COVID-19, even though this variant has mutations that help it escape antibodies. They found that most vaccinated and previously infected people maintained strong T cell responses to Omicron, but about one in five people showed significantly weakened T cell recognition of the virus. The weakened response occurred mainly in a specific type of T cell (CD8 cells) and was partly due to Omicron's mutations preventing these cells from detecting the virus. Booster shots improved T cell responses to Omicron. This matters because while Omicron can evade antibody protection, most people's T cells still work against it—meaning their immune system retains a crucial backup defense, though some individuals may be at higher risk.

Plain English
Researchers used a genetic test on tumor tissue samples to identify specific gene mutations called "fusions" (where two genes abnormally stick together) in rare jaw tumors called clear cell odontogenic carcinomas. They found that all three of these tumors contained fusions involving a gene called EWSR1, paired with other genes like ATF1 or CREM, which are known to drive cancer growth. This matters because it confirms that these rare jaw tumors are caused by the same genetic defects, which could eventually help doctors diagnose and treat them more accurately.

Plain English
Researchers measured virus DNA in the blood of throat cancer patients before and after surgery to see if it could predict whether cancer remained in their bodies. They found that patients whose blood virus levels dropped to nearly zero within one day after surgery stayed cancer-free, while patients with high virus levels one day after surgery had leftover cancer cells that needed additional treatment. This matters because a simple blood test done one day after surgery could tell doctors which patients need follow-up chemotherapy or radiation, potentially personalizing treatment and improving outcomes.

Plain English
Researchers tested whether people's immune T cells (a type of white blood cell that fights infection) could still recognize the Omicron COVID variant, even though this variant has mutations that escape antibodies. They found that most vaccinated and previously infected people maintained strong T cell recognition of Omicron, but about 21% of people showed a significant drop in T cell response to the variant—particularly in a specific type of T cell called CD8. A booster shot strengthened these T cell responses against Omicron. **Why it matters:** While Omicron can evade the antibodies that neutralize virus particles, the body's T cell defenses remain largely intact for most people, which is important for preventing severe illness.

Plain English
Researchers tested blood samples from people vaccinated against COVID-19 to see if their antibodies could fight the new Omicron variant, which has many mutations that make it look different to the immune system. Most people who got the original vaccine series couldn't neutralize Omicron at all, but those who received a booster shot—especially with mRNA vaccines—produced antibodies that still worked against it, though not quite as well as against the original virus. The findings show that booster shots are necessary to train your immune system to recognize and fight highly mutated variants of COVID-19, not just the original strain.

Plain English
Researchers tested how well COVID-19 vaccines protected cancer patients against different coronavirus variants, comparing three vaccine types across 178 patients who received initial doses and some who got boosters. They found that cancer patients had weaker immune responses to variant strains than to the original virus, but the Moderna vaccine (mRNA1273) performed best, followed by Pfizer (BNT162b2), then Johnson & Johnson (Ad26.COV2.S)—and these rankings held true across all variants tested. A booster shot significantly improved protection against multiple variants, and patients who developed higher antibody levels had the broadest protection, meaning their immunity worked against more variant types.

Plain English
Researchers tested whether a drug called palbociclib could shrink brain tumors that had spread from cancer elsewhere in the body, specifically in patients whose tumors had mutations affecting a protein pathway called CDK. The drug worked—it successfully shrank these brain tumors in patients who had the right genetic mutations. This matters because it shows doctors should test brain tumors for CDK mutations, since patients with these mutations can benefit from palbociclib rather than going straight to chemotherapy or radiation.